First malaria vaccine enters clinical trial in Ireland
The Royal College of Surgeons in Ireland is leading the study
The aim of the trial is to determine whether the vaccine is safe and produces an immunological response to malaria.
The Royal College of Surgeons in Ireland (RCSI) is heading the clinical trial in collaboration with the Jenner Institute at Oxford University in the UK.
The European Vaccine Initiative (EVI), a European Economic Interest Grouping (EEIG), is funding the trial.
Professor Sam McConkey, principal investigator and head of the department of International Health and Tropical Medicine at the RCSI, says malaria parasites are becoming resistant to today’s drugs, which has complicated the treatment of malaria and created a need for expensive multi-drug therapy.
‘In low income countries where malaria is endemic, expensive multi-drug therapy is often not an available treatment option so there is a need for new preventative treatments,’ he said.
Previous studies found vaccines could temporarily and partially prevent infection and clinical malaria for 18 months.
However, the new study aims to offer a vaccine that will offer long-term protection, reducing the mortality rates from malaria and moving towards eradication of the disease.
To date, 18 people have volunteered for a pre-enrolment health check-up, and 9 people have begun the study.
Further healthy adults who have not had malaria are needed and people interested in finding out more can visit the RCSI website for further information.
The first results from the trial are expected later this year.
The next step will be to establish the effectiveness of the vaccine in a phase IIa challenge model and through a phase IIb study in a country where malaria is common, with 200–300 adults.
You may also like
Trending Articles
You may also like
Research & Development
CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration
Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Regulatory
Grifols gets nod from European Medicines Agency for entire value chain of Grifols Egypt
The institution's certification endorses the entire plasma value chain under the highest European standards and opens the door for Egypt to, once domestic needs are met, export to other markets including Europe
Regulatory
Regulating innovation: a new focus on digital mental health technologies (DMHTs)
IMed Consultancy’s Benjamin Austin provides a clear understanding of how digital mental health technologies are innovating care and describes the evolving regulatory frameworks that ensure their safety and effectiveness